GlassScriptPhysician profile
Michaela B Koontz
NPI 1487866786
$577.85
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.25 · 2021: $75.41 · 2022: $471.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $144.27 | 2019-2022 | |
| Biomarin Pharmaceutical INC. | $117.82 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $108.95 | 2022 | |
| Abbvie INC. | $57.20 | 2022 | |
| Tandem Diabetes Care, INC. | $34.72 | 2022 | |
| Pfizer INC. | $32.70 | 2021-2022 | |
| Dexcom, INC. | $24.57 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $23.70 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.01 | 2022 | |
| Insulet Corporation | $12.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Koontz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.